Table 2.
Frequency of PIK3CA and ERBB family mutations detected in the largest cancer studies listed on www.cbioportal.org (n = 3454). The cancer subsets selected for this analysis must have a frequency of ERBB family mutations over 12%.
| Study/cancer type | % PIK3CA | % EGFR | % ERBB2 | % ERBB3 | % ERBB4 |
|---|---|---|---|---|---|
| Bladder urothelial carcinoma (TCGA)78 | 20.0 | 1.5 | 9.0 | 11.0 | 4.0 |
| Cervical squamous cell carcinoma and endocervical adenocarcinoma (TCGA, provisional) | 27.0 | 2.1 | 5.0 | 6.0 | 2.1 |
| Colorectal adenocarcinoma (DFCI)79 | 21.0 | 4.0 | 6.0 | 6.0 | 5.0 |
| Esophageal carcinoma (TCGA, provisional) | 10.0 | 2.7 | 6.0 | 3.0 | 9.0 |
| Head and neck squamous cell carcinoma (TCGA)80 | 21.0 | 5.0 | 1.8 | 2.9 | 5.0 |
| Pan-lung cancer (TCGA)81 | 8.0 | 10.0 | 2.3 | 2.4 | 9.0 |
| Stomach adenocarcinoma (TCGA)82 | 20.0 | 5.0 | 5.0 | 11.0 | 13.0 |
| Skin cutaneous melanoma (TCGA, provisional) | 3.0 | 7.0 | 2.5 | 2.2 | 16.0 |
| Uterine corpus endometrioid carcinoma (TCGA)83 | 53.0 | 3.0 | 3.0 | 7.0 | 6.0 |